A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Amount of NKTR-118 in Blood
Variation in the Heart's Electrical Cycle

Interventions

DRUG: NKTR-118
DRUG: moxifloxacin
DRUG: Placebo

Sponsor

AstraZeneca